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ABSTRACT
Introduction: The clinical benefits of biologic
and oral treatments for moderate-to-severe pla-
que psoriasis are well-established, but efficacy
outcomes can vary across therapies. Compara-
tive efficacy analysis can be highly informative
in clinical settings with multiple therapeutic
options. This study assessed the short-term and
long-term comparative efficacy of biologic and
oral treatments for moderate-to-severe psoriasis.
Methods: A systematic literature review identi-
fied phase 2/3/4 randomized controlled trials
(RCTs) through to 1 July 2020 for Food and
Drug Administration- or European Medicines
Agency-licensed treatments for moderate-to-
severe psoriasis. Psoriasis Area and Severity
Index (PASI) 75/90/100 response rates at the
end of the primary response (short-term: 10–-
16 weeks from baseline) and maintenance peri-
ods (long-term: 48–52 weeks from baseline)
were estimated using Bayesian network meta-
analysis. Surfaces under the cumulative ranking
curves (SUCRA) were estimated to present the
relative ranking of treatments.
Results: In the short term (N = 71 RCTs), the
PASI 90 response rates were highest for ixek-
izumab (72.9%, SUCRA 0.951), risankizumab
(72.5%, 0.940), and brodalumab (72.0%, 0.930),
which were significantly higher than those for
guselkumab (65.0%, 0.795), secukinumab
(65.0%, 0.794), infliximab (56.8%, 0.702), cer-
tolizumab (400 mg: 49.6%, 0.607; 200 mg:
42.2%, 0.389), ustekinumab (90 mg: 47.9%,
0.568; weight-based: 45.7%, 0.505; 45 mg:
44.6%, 0.460), adalimumab (43.0%, 0.410), til-
drakizumab (200 mg: 39.7%, 0.327; 100 mg:
37.2%, 0.268), etanercept (18.0%, 0.171),
apremilast (12.4%, 0.090), and dimethyl fuma-
rate (12.2%, 0.092). The PASI 100 response rates
were highest for ixekizumab (41.4%),
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risankizumab (40.8%), and brodalumab
(40.3%). In the long term (N = 11 RCTs), the
PASI 90 rate was highest for risankizumab
(85.3%, SUCRA: 0.998), which were signifi-
cantly higher than those for brodalumab
(78.8%, 0.786), guselkumab (78.1%, 0.760),
ixekizumab (72.1%, 0.577), secukinumab
(67.0%, 0.450), ustekinumab (weight-based:
55.0%, 0.252), adalimumab (51.6%, 0.176), and
etanercept (37.9%, 0.001). Risankizumab had
the highest PASI 100 response rate (65.4%),
followed by brodalumab (55.7%) and guselk-
umab (54.8%).
Conclusions: Ixekizumab, risankizumab, and
brodalumab had the highest short-term effi-
cacy, and risankizumab had the highest long-
term efficacy.
Keywords: Biologic therapies; Network meta-
analysis; Plaque psoriasis
Key Summary Points
Why carry out this study?
A comparative efficacy analysis of the
clinical benefits of biologic and oral
treatments for moderate-to-severe plaque
psoriasis can help inform treatment
decisions when multiple therapeutic
options are available.
This study assessed the short-term and
long-term comparative efficacy of biologic
and oral treatments for moderate-to-
severe plaque psoriasis licensed by the US
Food and Drug Administration or
European Medicines Agency using data
from their phase 2, 3, or 4 randomized
controlled trials.
Psoriasis Area and Severity Index (PASI)
75/90/100 response rates at the end of the
primary response period (short-term:
10–16 weeks from baseline) and the
maintenance period (long-term:
48–52 weeks from baseline) were
estimated using Bayesian network meta-
analysis.
What was learned from the study?
In the short term (N = 71 trials), the PASI
response rates were highest for
ixekizumab, risankizumab, and
brodalumab; in the long term (N = 11
trials), the PASI response rates were
highest for risankizumab.
Ixekizumab, risankizumab, and
brodalumab had the highest short-term
efficacy, and risankizumab had the
highest long-term efficacy.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.14102903.
INTRODUCTION
Novel biologic therapies have shifted the treat-
ment paradigm for moderate-to-severe plaque
psoriasis [1–3]. Anti-tumor necrosis factor (TNF)
agents (e.g., etanercept, infliximab, and adali-
mumab) and an anti-interleukin (IL) 12/23
agent (ustekinumab) were among the earliest
biologic treatments licensed by the US Food and
Drug Administration (FDA) and the European
Medicines Agency (EMA) for psoriasis. In recent
years, biologic drugs targeting IL-17 (ixek-
izumab, brodalumab, and secukinumab) and IL-
23 (risankizumab, guselkumab, and tildrak-
izumab) have become available and expanded
the therapeutic options for psoriasis.
To facilitate the selection of appropriate
treatment regimens among the available can-
didates, it is important to evaluate multiple
aspects of each treatment, including the effi-
cacy, safety, treatment adherence, and health-
related quality of life (HRQoL), and to consider
the contraindications of the target patient
population [4]. Specifically, the comparative
efficacy data, particularly a high level of skin
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clearance as an outcome (i.e., a 90 or 100%
reduction in Psoriasis Area and Severity Index
[PASI 90, PASI 100, respectively]), are of key
interest. These efficacy outcomes have been
associated with improvement in HRQoL, psori-
asis symptoms, and work productivity. For
example, Elewski et al. [5] reported that patients
who achieved PASI 90–100 at week 12 in the
ERASURE and FIXTURE trials were more likely
to achieve a sustained response in HRQoL
measured by the Dermatology Life Quality
Index. Viswanathan et al. [6] showed that
patients who achieved PASI 100 response at
week 12 in a clinical trial had significantly lower
psoriasis symptom severity [6]. Feldman et al.
[7] showed that employed patients in the
CLEAR trial who achieved at least PASI 90 had
significantly lower work productivity loss and
reduced annual indirect costs. Outcomes
assessing a high level of skin clearance have also
become increasingly used in clinical develop-
ment programs [8–11], making it possible to
conduct an indirect comparison of such out-
comes associated with various treatments.
While several recent network meta-analyses
(NMAs) have been conducted to compare the
relative efficacy of treatments for moderate-to-
severe plaque psoriasis, knowledge gaps still
exist [12–19]. First, PASI 100 results were not
available in some of the recent NMAs [13, 15].
Second, such NMAs may lack sufficient statisti-
cal power to detect potential differences
between treatments with the highest PASI 90
and 100 response rates. Third, comparative
evidence assessing the long-term efficacy of
treatments is limited due to the dearth of head-
to-head trials that did not implement crossover
or re-randomization in the study design [14].
Expert opinions have stressed the importance of
maintaining long-term skin clearance, even if
short-term skin clearance is achieved [20].
Compared with the short-term PASI response,
the long-term PASI response can additionally
reflect the variation in response over time,
accounting for the gradual loss of response
among some patients.
Recently, several large head-to-head trials
have been published that compare various
novel treatments for psoriasis, including
IXORA-R comparing ixekizumab with
guselkumab [8], ECLIPSE comparing guselk-
umab with secukinumab [21], CLARITY com-
paring secukinumab with ustekinumab [22],
and IMMerge comparing risankizumab with
secukinumab [9]. Incorporating these studies in
an indirect comparison of the PASI response
rates may not only improve the statistical power
to detect differences in both short- and long-
term PASI response rates, but also enhance and
inform the evidence network for comparisons
of long-term treatment efficacy. To this end,
this study updated the NMA conducted by
Armstrong et al. [14] by incorporating recently
published clinical trial data to provide a com-
prehensive assessment of the short-term and
long-term PASI response rates, including PASI
90 and 100 as outcomes, associated with




A systematic literature review (SLR) was con-
ducted to identify randomized controlled clin-
ical trials of treatments for moderate-to-severe
psoriasis through to 1 July 2020, which was an
update of the SLR by Armstrong et al. [14]. The
search strategy is detailed in the Methods sec-
tion of the electronic supplementary material.
Eligible trials were required to (1) be a phase 2,
3, or 4 randomized clinical trial (RCT) on
treatments for moderate-to-severe plaque pso-
riasis among adults who were eligible for sys-
temic therapies or phototherapy; (2) include
treatments and dosages licensed by the US FDA
or the EMA; and (3) report at least one of the
efficacy outcomes of interest (PASI 75, 90, and
100; indicating the proportions of patients who
achieved at least a 75, 90, or 100% reduction in
PASI) by the end of the primary response period
(short-term: 10–16 weeks from baseline) or the
end of the maintenance period (long-term:
48–52 weeks from baseline). For the long-term
NMA, trials were excluded if (1) patients swit-
ched to a different treatment during the post-
induction period compared with the induction
period; (2) patients received a different dosage
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during the post-induction period compared
with the induction period, such that the entire
treatment regimen considering both the
induction period and the post-induction period
was not licensed; or (3) patients were re-ran-
domized based on certain efficacy criteria, such
as PASI 75, during the post-induction period.
As this is a post-hoc NMA of previously
published results of clinical trial data, no insti-
tutional board review was required. This article
is based on previously conducted studies and
does not contain any new studies with human
participants or animals performed by any of the
authors.
Comparators
The comparators in this study included anti-IL-
23 agents (guselkumab 100 mg at weeks 0 and 4,
then every 8 weeks; risankizumab 150 mg at
weeks 0 and 4, then every 12 weeks; tildrak-
izumab 100 mg and 200 mg at weeks 0 and 4,
then every 12 weeks), anti-IL-17 agents (bro-
dalumab 210 mg at weeks 0, 1, and 2, then
every 2 weeks; ixekizumab 160 mg at week 0,
80 mg every 2 weeks until week 12, then 80 mg
every 4 weeks; secukinumab 300 mg at weeks 0,
1, 2, 3, and 4, then every 4 weeks), anti-TNF
agents (adalimumab 80 mg at week 0, then
40 mg every 2 weeks starting at week 1; cer-
tolizumab 400 mg at weeks 0, 2, and 4, then
200 mg or 400 mg every 2 weeks; etanercept
25 mg twice-weekly/50 mg weekly; infliximab
5 mg/kg at weeks 0, 2 and 6, then every
8 weeks), an anti-phosphodiesterase type 4
inhibitor (PDE4) agent (apremilast 30 mg twice
daily after the initial titration schedule), an
anti-IL-12/23 agent (ustekinumab 45 mg,
90 mg, or with a weight-based dosage
[45 mg B 100 kg, 90 mg[ 100 kg] at weeks 0
and 4, then every 12 weeks), as well as dimethyl
fumarate uptitrated to a maximum daily dose of
720 mg for the treatment of moderate-to-severe
plaque psoriasis.
Outcomes
The outcomes were the proportions of patients
who achieved PASI 75, 90, and 100 response by
the end of the pre-specified primary assessment
period for the short-term NMA (weeks 10–16
after baseline) and the end of the pre-specified
maintenance period for the long-term NMA
(weeks 48–52 after baseline). The number nee-
ded to treat (NNT) for each treatment relative to
placebo by the end of the primary assessment
period was also calculated. These pre-specified
periods for the primary assessment period and
maintenance period were chosen because the
studies for the various medications were
designed and a priori powered for those time
periods. Additionally, these time points often
corresponded to the primary or secondary end-
points of the clinical trials.
Statistical Analyses
NMA Models
Bayesian probit NMAs [23] were implemented
to jointly model the PASI 75, 90, and 100
response rates. Due to the rich set of clinical
trials in the short-term network, a reference-arm
adjustment was implemented to account for
potential cross-trial heterogeneities in treat-
ment effects associated with the placebo
response rate of each trial [19, 24]. Additionally,
a random-effects model was applied to the
short-term NMA to account for the potential
heterogeneities that cannot be explained by
placebo response rates. For the long-term NMA,
a fixed-effects NMA model was fit due to the
relative sparsity of the network.
For each treatment, the posterior distribu-
tions of the PASI 75, 90, and 100 response rates
in the short term (10–16 weeks after baseline)
and the long term (48–52 weeks after baseline)
were summarized using posterior medians and
95% credible intervals (CrI). As the response
rates were correlated, an overlap in two CrIs did
not rule out the possibility of a statistically sig-
nificance difference between two treatments.
Therefore, odds ratios (ORs) were used to for-
mally compare the PASI response rates between
each pair of treatments and were summarized
using posterior medians and 95% CrIs. Addi-
tionally, the treatments were ranked using the
surface under the cumulative ranking curve
(SUCRA) and mean rank with 95% CrI [25].
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For the short-term NMA, the NNT for each
treatment relative to the placebo was calculated
as the reciprocal of difference of a treatment in
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Fig. 1 Study screening and selection flow. e1 exclusion 1, e2 exclusion 2, i1 inclusion 1, i2 inclusion 2, i3 inclusion 3, NMA
network meta-analysis
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Fig. 2 Evidence network for the network meta-analysis
(NMA) of the Psoriasis Area and Severity Index (PASI)
response by the end of the primary response period (short-
term; 10–16 weeks after baseline). The included trials were:
Asahina et al. [27], Bissonnette et al. [28], REVEAL [29],
CHAMPION [30], Gordon et al. [31], Cai et al. [32], VIP
[33], Leonardi et al. [34], Papp et al. [35], van de Kerkhof
et al. [36], Gottlieb et al. [37], EXPRESS [38], EXPRESS II
[39], SPIRIT [40], Chaudhari et al. [41], Torii et al. [42],
Yang et al. [43], UNCOVER 1 [44], UNCOVER 2 [45],
UNCOVER 3 [45], IXORA-S [10], IXORA-R [8],
ERASURE [46], FEATURE [47], FIXTURE [46], JUNC-
TURE [48], CLEAR [49], CLARITY [11], VIP-S [50],
ALLURE [51], ObePso-S [52], NCT03066609 [53],
ACCEPT [54], LOTUS [55], PEARL [56], PHOENIX 1
[57], PHOENIX 2 [58], Igarashi et al. [59], VIP-U [60],
Zhou et al. [61], X-PLORE [62], VOYAGE-1 [63],
VOYAGE-2 [64], ORION [65], Ohtsuki et al. [66],
ECLIPSE [21], Nakagawa et al. [67], Papp et al. [68],
AMAGINE-1 [69], AMAGINE-2 [70], AMAGINE-3
[70], CIMPASI-1 [71], CIMPASI-2 [71], CIMPACT
[72], NCT00245765 [73], NCT03051217 [74], reSUR-
FACE-1 [75], Papp et al. [76], reSURFACE-2 [75],
UltIMMa1 [77], IMMvent [78], IMMhance [79], Sus-
talMM [80], IMMerge [9], BRIDGE [81], PSOR-008/
ESTEEM-1 [82], PSOR-009/ESTEEM-2 [83], PSOR-010/
LIBERATE [84], PSOR-005 [85], and Ohtsuki et al. [86].
BIW Twice weekly, QW once weekly
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Additionally, the heterogeneity in treatment
contrasts for the short-term NMA was summa-
rized using (1) the posterior distribution mea-
suring the effect of placebo response on
treatment contrasts and (2) the posterior distri-
bution measuring the residual cross-trial vari-
ance in treatment contrasts.
Computation
The posterior samples of the Bayesian NMA
models were drawn using the Markov Chain
Monte Carlo technique. Three parallel chains,
each with 5000 adaptation iterations, 50,000
burn-in iterations, 50,000 posterior simulations,
and a thinning factor of 10, were implemented.
Vague prior distributions were applied for all
parameters, such that the posterior distributions
were driven primarily by the observed data. All
analyses were conducted in R statistical software
(version 3.5.1; R Foundation for Statistical Com-
puting, Vienna, Austria) and JAGS 4.3.0 (Free
Software Foundation, Inc., Boston, MA, USA)
RESULTS
Literature Search
A total of 464 publications covering 195 studies
were identified in the SLR through to 1 July
2020, with 71 studies included in the NMAs and
124 studies excluded from the NMAs (Fig. 1). All
71 studies were included in the short-term
NMA, and 11 of the 71 studies were included in
the long-term NMA. Compared with the SLR
conducted by Armstrong et al. [14], 52 addi-
tional records were identified, with 11 addi-
tional studies qualifying for the short-term
NMA and four additional studies qualifying for
the long-term NMA.
Short-term Efficacy
A total of 71 eligible RCTs connecting 18 treat-
ment regimens were included in the NMA of
short-term PASI response rates (10–16 weeks
after baseline) (Fig. 2). A list of the trials inclu-
ded in the short-term NMA is included in
Table S1 in the electronic supplementary
material.
The posterior medians of the PASI 90
response rates were highest for ixekizumab
(median 72.9% [95% CrI 68.3%, 77.1%]),
risankizumab (72.5% [68.1%, 76.7%]), and
brodalumab (72.0% [67.3%, 76.7%]), followed
by guselkumab (65.0% [60.3%, 69.7%]), secuk-
inumab (65.0% [61.0%, 68.7%]), infliximab
(56.8% [50.4%, 62.9%]), certolizumab 400 mg
(49.6% [43.0%, 56.3%]), ustekinumab 90 mg
(47.9% [41.4%, 54.2%]), ustekinumab weight-
based dosage (45.7% [41.2%, 50.3%]), ustek-
inumab 45 mg (44.6% [39.2%, 49.8%]), adali-
mumab (43.0% [38.7%, 47.4%]), certolizumab
200 mg (42.2% [35.3%, 49.4%]), tildrakizumab
200 mg (39.7% [33.2%, 46.8%]), tildrakizumab
100 mg (37.2% [30.8%, 44.1%]), etanercept
(18.0% [14.5%, 22.2%]), apremilast (12.4%
[9.7%, 15.9%]), and dimethyl fumarate (12.2%
[7.2%, 20.2%]) (Table 1). Similarly, the posterior
medians of the PASI 100 response rates were
highest for ixekizumab (median 41.4% [95% CrI
36.3%, 46.6%]), risankizumab (40.8% [36.1%,
46.0%]), and brodalumab (40.3% [35.2%,
46.1%]). SUCRA and mean rank suggested a
similar ranking of treatments as the median
PASI response rates. Ixekizumab, risankizumab,
and brodalumab were associated with the
highest SUCRA (0.951, 0.940, and 0.930,
respectively) and mean rank (1.8, 2.0, and 2.2,
respectively) (Table 1; and ESM Fig. S1).
The posterior distributions of the pairwise
ORs suggested that the PASI response rates were
comparable between ixekizumab, risankizumab,
and brodalumab, which were significantly
higher than those of all other treatments,
including guselkumab and secukinumab, with
95% probability (Table 2 [PASI 90 and 100]; ESM
Table S2 [PASI 75]). Guselkumab and secuk-
inumab were associated with significantly
higher PASI response rates compared with
infliximab, certolizumab (200 and 400 mg),
ustekinumab (45 mg, 90 mg, and weight-based),
adalimumab, tildrakizumab (100 and 200 mg),
etanercept, apremilast, and dimethyl fumarate,
with 95% probability.
The NNTs to achieve PASI 75, 90, or 100 for
each treatment relative to placebo are presented
in Fig. 3. The NNTs to achieve one additional
Dermatol Ther (Heidelb) (2021) 11:885–905 891
Table 1 Estimated response rates, SUCRA, and mean rank from the NMA of short-term PASI response
Treatment Posterior median, % (95% CrI) SUCRAa Mean rank
(95% CrI)PASI 75 PASI 90 PASI 100
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PASI 90 response were 1.39 (95% CrI 1.32, 1.49)
for ixekizumab, 1.40 (1.32, 1.49) for risankizu-
mab, and 1.41 (1.32, 1.51) for brodalumab. The
NNTs to achieve one additional PASI 100
response were 2.42 (95% CrI 2.15, 2.76) for
ixekizumab, 2.45 (2.18, 2.78) for risankizumab,
and 2.49 (2.18, 2.84) for brodalumab.
The random-effects model with reference-
arm adjustment revealed cross-trial hetero-
geneities in treatment contrasts. On the probit
scale, each unit increase in the placebo PASI
response rate was associated with a statistically
significant decrease of 0.750 (95% CrI 0.534,
1.008) in the difference between the active
treatment and placebo. The residual cross-trial
variance of treatment contrasts on the probit
scale was 0.014 (95% CrI 0.006, 0.028), which
differs from zero with 95% probability.
Long-Term Efficacy
A total of 11 eligible RCTs connecting eight
treatment regimens were included in the NMA
of long-term PASI response rates (48–52 weeks
after baseline) (Fig. 4). A list of the trials inclu-
ded in the long-term NMA is shown in ESM
Table S3.
The posterior PASI 90 response rates were
highest for risankizumab (median 85.3% [95%
CrI 81.4%, 88.7%]), followed by brodalumab
(78.8% [74.0%, 83.0%]), guselkumab (78.1%
[72.5%, 83.0%]), ixekizumab (72.1% [62.7%,
80.1%]), secukinumab (67.0% [62.8%, 71.0%]),
ustekinumab (weight-based 55.0% [52.7%,
57.3%]), adalimumab (51.6% [41.8%, 61.3%]),
and etanercept (37.9% [30.4%, 45.8%])
(Table 2). Similarly, the posterior PASI 100
response rates were highest for risankizumab
(median: 65.4% [95% CrI 59.3%, 71.1%]), fol-
lowed by brodalumab (78.1% [72.5%, 83.0%])
and guselkumab (54.8% [47.6%, 61.9%]).
SUCRA and mean rank suggested a consistent
ranking of treatments as the PASI response
rates, with risankizumab associated with a
SUCRA of 0.998 and a mean rank of 1.0, fol-
lowed by brodalumab and guselkumab (Table 3;
ESM Fig. S2).
The posterior distributions of the pairwise
odds ratios suggested that the PASI response
rates associated with risankizumab were signif-
icantly higher than all other treatments,
including brodalumab, guselkumab, ixek-
izumab, and secukinumab with 95% probability
(Table 4 [PASI 90 and 100] and Table S4 [PASI
75] in the electronic supplementary material).
Brodalumab and guselkumab were associated
with significantly higher PASI response rates
than ustekinumab, adalimumab, and etaner-
cept with 95% probability.
Table 1 continued
Treatment Posterior median, % (95% CrI) SUCRAa Mean rank
(95% CrI)PASI 75 PASI 90 PASI 100


























BID twice daily, BIW twice weekly, CrI credible interval, NMA network meta-analysis, PASI Psoriasis Area and Severity
Index, PASI 75, 90, 100 75, 90, or 100% decrease from baseline PASI, respectively, QW once weekly, Q2W once every
2 weeks, Q4W once every 4 weeks, Q8W once every 8 weeks, Q12W once every 12 weeks
a SUCRA (surfaces under the cumulative ranking curves) measures the probability of a treatment being in the top ranks
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Table 2 Pairwise odds ratio of achieving PASI 90 and 100 response in the short term
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Table 2 continued















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Values in table are presented as the pairwise odds ratio with the 95% credible interval in parenthesis. An odds ratio[ 1 indicates that the treatment in that
row has a higher probability of achieving PASI response compared with the treatment in that column. An odds ratio\ 1 indicates that the treatment in
that row has a lower probability of achieving PASI response compared with the treatment in that column
ADA adalimumab, APR apremilast, BRO brodalumab, CZP 200 certolizumab 200 mg, CZP 400 certolizumab 400 mg, DMF dimethyl fumarate, ETA
etanercept, GUS guselkumab, INF infliximab, IXE ixekizumab, PBO placebo, RIS risankizumab, SEC secukinumab, TIL 100 tildrakizumab 100 mg, TIL
200 tildrakizumab 200 mg, UST_W ustekinumab weight based, UST 45 ustekinumab 45 mg, UST 90 ustekinumab 90 mg
aDenotes that 95% CrI excludes 1
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DISCUSSION
The results suggest that ixekizumab, risankizu-
mab, and brodalumab were associated with
significantly higher PASI response rates than the
other licensed treatments in the short term, and
that risankizumab was associated with signifi-
cantly higher PASI response rates than the other
licensed treatments in the long term. The
results established the benefits of these treat-
ments towards achieving a high level of skin
clearance (PASI 100 and PASI 90).
Compared with the prior NMA by Armstrong
et al. [14], this study identified 11 additional
trials for the short-term PASI NMA and four
additional trials for the long-term PASI NMA.
These additions included several large head-to-
head trials between active treatments reporting
short-term PASI results, such as IXORA-R
(n = 1027) and ECLIPSE (n = 1048) [8, 21]. The
increase in statistical power made it possible to
detect previously unidentified significant dif-
ferences in PASI response rates between the
treatments. Specifically, the present study
found statistically significantly higher short-
term PASI response rates associated with ixek-
izumab, risankizumab, and brodalumab com-
pared with guselkumab following the addition
of the 11 recent trials. Furthermore, the four
newly added trials with long-term PASI results
extended the long-term NMA conducted by
Armstrong et al. [14] and further connected
guselkumab and adalimumab to facilitate an
indirect comparison of eight active treatments.
The large sample sizes of the newly included
head-to-head trials, such as CLARITY (n = 1102)
and ECLIPSE (n = 1048) [21, 22], also made it
possible for the present long-term NMA to
detect statistical differences between
treatments.
In the short-term NMAs of this study, two
anti-IL-17 agents (ixekizumab and brodalumab)
and an anti-IL-23 agent (risankizumab) were
associated with the most favorable efficacy
outcomes, including achievement of a high
level of skin clearance. This result is consistent
with the findings of other recent NMAs for
moderate-to-severe plaque psoriasis. For exam-
ple, Sbidian et al. [15] suggested that anti-IL-17
agents (ixekizumab, secukinumab, bimek-
izumab, and brodalumab), anti-IL-23 agents
(risankizumab and guselkumab), and infliximab
were significantly more effective, in terms of
PASI 90 response rates, than ustekinumab and
other anti-TNF agents (adalimumab, cer-
tolizumab, and etanercept). Mahil et al. [13]
showed that in terms of achieving clear/nearly
clear skin status, ixekizumab was associated
with the highest SUCRA value followed by
risankizumab. Sawyer et al. [12] reported that
the anti-IL-17 agents guselkumab and risanki-
zumab were more efficacious than tildrak-
izumab, ustekinumab, anti-TNF agents, and
non-biologic systemic treatments. Tada et al.
[17] similarly reported that brodalumab, ixek-
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Fig. 3 Estimated numbers needed to treat (NNTs) relative
to placebo for short-term PASI response. Values are
presented with the 95% credible interval (Crl) in
parenthesis. BIW Twice weekly, PASI 75, 90, 100 75,
90, or 100% decrease from baseline PASI, respectively, QW
once weekly
896 Dermatol Ther (Heidelb) (2021) 11:885–905
the highest rates of PASI 90 and PASI 100
response and the highest SUCRA values.
The long-term NMA suggested that PASI 90
and 100 response rates were highest for risan-
kizumab by the end of the maintenance period
(PASI 90: 85.3%; PASI 100: 65.4%), followed by
brodalumab and guselkumab. To date, few
studies have attempted an NMA comparing the
relative efficacy of treatments in the long term.
Yasmeen et al. [16] found that risankizumab,
brodalumab, and guselkumab were associated
with a higher probability of achieving a PASI
response than other biologics, but did not
detect statistically significant differences
between the three treatments.
This study benefits from the following
strengths. First, the inclusion of newly pub-
lished clinical trials permitted the addition of
guselkumab and adalimumab into the long-
term NMA and increased the sample sizes and
statistical power for detection of differences in
PASI response rates between treatments in both
the short-term and long-term NMAs. Second,
the use of the random-effects model adjusted
for reference-arm response for the short-term
NMAs addressed the potential heterogeneities
Fig. 4 Evidence network for the NMA of PASI response
by the end of the maintenance period (long-term;
48–52 weeks after baseline). The included trials were:
AMAGINE-2 [70], ECLIPSE [21], VOYAGE-1 [63],
CLEAR [87], FIXTURE [46], CLARITY [22], IXORA-S
[88], UltIMMa1 [77], and IMMerge [9]
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in treatment contrasts across trials, and insured
the validity for the statistical inference for the
short-term NMAs under a rich network.
Limitations
This study is subject to the following limita-
tions. First, NMAs rely on the transitivity
assumption, requiring that the study conduct
and patient populations be comparable across
trials. There may be observed or unobserved
factors, such as differences in study design,
patient characteristics, and concomitant treat-
ments, that may modify the treatment efficacy
and influence the comparability of the clinical
trials in the NMAs. The assessment time points
also varied across trials. However, as the
included clinical trials were designed a priori for
the assessments at these time points, these pre-
specified time points were chosen for this
analysis. Second, the potential differences
between patients with moderate-to-severe pla-
que psoriasis in the clinical trials and the real
world, such as patient characteristics, adher-
ence, and persistence to treatments, may limit
the generalizability of the study results [26].
Third, due to the relative dearth of available
data, the long-term network is still sparse.
Fourth, while the long-term NMA was able to
assess the relative efficacy of treatments by
48–52 weeks after baseline, direct evidence
comparing the PASI response rates beyond
1 year is lacking. Lastly, PASI may only repre-
sent one of the many aspects measuring the
Table 3 Estimated response rates, SUCRA, and mean rank from the NMA of long-term PASI response
Treatment Posterior median, % (95% CrI) SUCRAa Mean rank
(95% Crl)PASI 75 PASI 90 PASI 100
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efficacy of treatments for moderate-to-severe
plaque psoriasis. With additional data, future
studies may consider comparisons of other
measures of treatment efficacy, such as the res-
olution of itch, HRQoL, and treatment
adherence.
CONCLUSIONS
This study provides an up-to-date, comprehen-
sive indirect comparison of the relative efficacy
of licensed treatments for moderate-to-severe
plaque psoriasis. Ixekizumab, risankizumab,
and brodalumab were associated with the
highest PASI response rates by the end of the
primary response period. Risankizumab was
associated with the highest PASI response rates
by the end of the maintenance period. Future
research can take an integrative approach to
assess multiple aspects of each treatment,
including efficacy, safety, treatment adherence,
and HRQoL, and identify subgroups of patients
(using clinical, laboratory, and genomic data)
who can benefit the most from each biologic
and oral treatment for moderate-to-severe pla-
que psoriasis.
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